In vitro three dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents.

Brad Shrum, Penny Costello, Warren McDonald, Christopher Howlett, Marisa Donnelly, Vivian C McAlister

Abstract read

In one paragraph

Article in Hepatobiliary surgery and nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Characterization of the mechanical properties of cancer cells in 3D matrices in response to collagen concentration and cytoskeletal inhibitors.Integrative biology : quantitative biosciences from nano to macro · 2018
Article
Magnesium isoglycyrrhizinate ameliorates doxorubicin-induced acute cardiac and hepatic toxicity via anti-oxidant and anti-apoptotic mechanisms in mice.Experimental and therapeutic medicine · 2018
Article
A novel chemotherapeutic sensitivity-testing system based on collagen gel droplet embedded 3D-culture methods for hepatocellular carcinoma.BMC cancer · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Brad Shrum1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Penny Costello1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Warren McDonald1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Christopher Howlett1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Marisa Donnelly1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Vivian C McAlister1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding the prognosis of hepatocellular carcinoma (HCC) informs plans for care. Tumor morphology and molecular markers have been correlated with outcomes. Three-dimensional tissue culture (3DTC) allows for direct in vitro measurement of a tumor's ability to grow and metastasize. The impact of chemotherapeutic agents, alone or in combinations, may also be measured.

methodsAll patients with a presumed diagnosis of HCC were eligible for this study including those undergoing resection, chemoembolization and transplantation. Concomitant diseases and outcomes were recorded. One mm(3) HCC specimens were grown in multiwell plates containing gel media, without and with chemotherapeutic agents.

resultsTumors were sampled from 17 patients. Only 13 had HCC, all of whom had liver transplantation. Of the confirmed HCC patients, 6 (46%) are alive and disease free 82 months following transplantation, 1 (7%) is alive with recurrence of disease and 6 (46%) died, with a mean survival of 12 months post liver transplant. Ten of thirteen 3DTC samples grew, having an average migration distance of 108.3µm in the first 24 hours. Two of three patients who had prior chemoembolization had successful 3DTC. Migration distances (µm) were 188.8±104.3, 104.5±111.7 and 39.6±32.4 for tumors categorized as high, intermediate and low grade, respectively. Tumor migration was inhibited by irinotecan, paclitaxel and docetaxel (-68%±7%, -61%±19% and -60%±21%, respectively) whereas the effect was variable with 5 fluorouracil (5FU) and doxorubicin (-12%±51% and 9%±76%, respectively).

conclusionsIt is feasible to grow tissue from HCC in 3DTC to study the tumor's capacity to grow and migrate and its responsiveness to commonly used chemotherapeutic protocols.

Indexed as

Cancerchemotherapyhepatocellular carcinoma (HCC)survivalthree-dimensionaltissue culturetransplant

Identifiers

PMID27275461

DOI10.21037/hbsn.2016.01.01

PMCPMC4876253

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.